Clinical Trial Update: A Study of rhGAA in Patients With Late-Onset Pompe Disease [Phase 2]

View source ↗

Summary

Phase 2 study of recombinant human acid alpha-glucosidase (rhGAA) in patients with late-onset Pompe disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II) | Phase 2 | Status: COMPLETED